Findings of the TIA cohort showed that anti-phosphatidylserine/prothrombin IgG antibodies are associated with clinical outcomes after TIA in patients without antiphospholipid antibody syndrome [54]. This evidence concerns the gene F2 and antiphospholipid syndrome.